The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
S1701: A randomized phase II trial of carboplatin-paclitaxel with and without ramucirumab in patients with locally advanced, recurrent, or metastatic thymic carcinoma.
 
Anne S. Tsao
Honoraria - Aptitude Health; ARIAD; AstraZeneca; BioAscent; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Genentech; Gilead Sciences; GlaxoSmithKline; Medscape; Merck; MJH Life Sciences; Novartis; Novocure; Oncohost; Pfizer; Roche; Summit Therapeutics; UpToDate
Consulting or Advisory Role - ARIAD; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; Gilead Sciences; GlaxoSmithKline; Merck; Novartis; Pfizer; Roche; Summit Therapeutics
Research Funding - ARIAD; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; Lilly; Merck; Novartis; Polaris; Seattle Genetics/Astellas
 
Ming-Hui Hsieh
No Relationships to Disclose
 
Marianna Koczywas
No Relationships to Disclose
 
Janet Chen Tu
No Relationships to Disclose
 
Jonathan W. Riess
Consulting or Advisory Role - Amgen; Bayer; BeiGene; Biodesix; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Catalyst Clinical Research; Daiichi Sankyo; EMD Serono; Genentech; Janssen Oncology; Merck; Merus NV; Novartis; OncoCyte; Regeneron; Sanofi; Seagen; Turning Point Therapeutics
Research Funding - ArriVent Biopharma (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); IO Biotech (Inst); Kinnate Biopharma (Inst); Merck (Inst); Novartis (Inst); Revolution Medicines (Inst); Spectrum Pharmaceuticals (Inst); Summit pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca; IO Biotech
 
Tawee Tanvetyanon
No Relationships to Disclose
 
Barbara Ting-wen Ma
No Relationships to Disclose
 
Yingqi Zhao
No Relationships to Disclose
 
Mary Weber Redman
No Relationships to Disclose
 
Martin Joseph Edelman
Stock and Other Ownership Interests - Biomarker Strategies; Creatv MicroTech
Consulting or Advisory Role - BioAtla; Coherus Biosciences; GE Healthcare; Omega Therapeutics
Patents, Royalties, Other Intellectual Property - Patent application for radiopharmaceutical to treat small cell lung cancer. (Inst)
Other Relationship - Anheart Therapeutics; AstraZeneca/MedImmune; Boehringer Ingelheim; Seagen; Takeda
 
David R. Gandara
Honoraria - Merck
Consulting or Advisory Role - Adagene (Inst); AstraZeneca (Inst); Guardant Health (Inst); Guardant Health (Inst); IO Biotech (Inst); OncoCyte (Inst); OncoHost (Inst); Roche/Genentech (Inst)
Research Funding - Amgen (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Genentech (Inst); Merck (Inst)
 
Karen Kelly
Patents, Royalties, Other Intellectual Property - Author Royalties for UpToDate, an evidence based, peer reviewed information resource, available via the web, desktop, and PDA.
 
Jhanelle E. Gray
Honoraria - AstraZeneca; Daiichi Sankyo, Inc; EMD Serono/Merck; Flatiron Health; Gilead Sciences; Gilead Sciences; IDEOlogy Health; Janssen Scientific Affairs; Jazz Pharmaceuticals; Merck; Merck; OncoCyte; Pfizer; Regeneron; Spectrum ODAC; Triptych Health Partners
Consulting or Advisory Role - Abbvie; AstraZeneca; Daiichi Sankyo/UCB Japan; Flatiron Health; Gilead Sciences; Gilead Sciences; IDEOlogy Health; Jazz Pharmaceuticals; Merck; Merck; Pfizer; Regeneron; Spectrum Pharmaceuticals; Triptych Health Partners
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Services (Inst); Lilly (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Novartis (Inst); Panbela Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Abbvie; OncoCyte; Spectrum Pharmaceuticals